Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase 1 2Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 7Neutropenia 3Lymphoma, Non-Hodgkin 2Ovarian Neoplasms 1Malignant Solid Tumors 1Lymphoma 1Lung Neoplasms 1Fever 1Carcinoma, Non-Small-Cell Lung 1

Interventions

niraparib 4olaparib 2apatinib 2Sevoflurane 2Saline Solution 2Propofol 2Carboplatin 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1palbociclib 1liposomal doxorubicin 1lenvatinib 1gadofosveset trisodium 1fosaprepitant 1ferrous fumarate 1Tranexamic Acid 1Trabectedin 1Sunitinib 1Sodium Chloride 1Pharmacokinetics 1Patient-Specific Modeling 1Pafolacianine 1Paclitaxel 1LY 353381 1Injections 1Indocyanine Green 1Folic Acid 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Ovarian Neoplasms × pegfilgrastim × Clear all
NCT00277160 2010-10-08

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Amgen

Phase 4 Completed
852 enrolled
BreastGynecologicLymphoidThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neutropenia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡